aprotinin and Myocardial-Infarction

Topics: alpha 1-Antitrypsin Deficiency; Animals; Aprotinin; Asthma; Bacterial Infections; Blood Coagulation Disorders; Burns; Drug Evaluation; Drug Therapy, Combination; Humans; Influenza, Human; Kallikreins; Myocardial Infarction; Myocarditis; Pancreatitis; Peptides; Pneumonia, Staphylococcal; Shock; Tissue Extracts; Trypsin Inhibitors

The aim is to show the effectiveness of inhibitors of the kallikrein-kinin system (KKS) to avoid early microcirculation impairment and low reperfusion damages in the ischemic area during systemic thrombolysis (T) in order to achieve optimal results of thrombolytic therapy (TLT) in patients with acute myocardium infarction. Patients (n=104) with acute myocardium infarction were divided into 4 groups: treatment with early TLT infusing Contrycal (Aprotinin) and Heparin (CH) during the first 2 hrs from the onset of disease (Gr. 1); treatment for isolated T at an early stage (Gr. 2); TLT with late T (in 3-6 hrs) (Gr. 3); and conventional therapy (Gr. 4). The dynamics of clinical and ECG data were evaluated for each of the groups. Before the clinical study was fully evaluated, an experimental-morphological, controlled study was carried out on dogs. These results showed improved retrograde blood flow of the acute ischemized myocardium and decrease in ischemia level, together with reduction of frequency and area of reperfused intramiocardial haemorrhages (RPIMH) in infarction areas under the TLT and CH infusion. When CH was infused a significant advantage was revealed in early T that showed high antianginal and antiarrhythmic effect, while no Q wave was observed or it was deepened non-significantly. More clinical dynamic problems with extrasystols and significant deepening of Q wave were seen in the earlier isolated T (Gr. 2) that were worse than those seen in Gr. 1 conditions, but the problems were more negative in the patients from Gr. 3 and 4. CH optimizes the situation causing suppression of the pathological activation of KKS, decreasing vessel permeability, and reducing reperfusion damage. The latest thrombolytic drugs ensure faster thromb lysing but do not prevent the reperfusion damage, as higher fibrinolytic activity at the moment of T causes enhanced activation of KKS and RPIMH development and prevents peroxide oxidation of the lipids but this may result in higher affectivity of antioxidant use. Earlier administration of KKS inhibitors optimizes the affectivity of TLT and widens the indication to the systemic and intracoronary T, minimizes complications, and may cause higher affectivity of coronary angioplasty (CAP) and aorta-coronary shunting in patients with acute myocardium infarction.

Topics: Adult; Aged; Aprotinin; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Infusions, Intravenous; Kinins; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Severity of Illness Index; Streptokinase; Thrombolytic Therapy; Treatment Outcome; Trypsin Inhibitors

One hundred and forty-nine of 199 patients with myocardial infarction (MI) were treated with varying doses of kallikrein-protease inhibitors (KPI), contrical or gordox, for 4 to 5 days as part of combined treatment. KPI added to combined treatment at early dates of MI contributed significantly to the elimination or abatement of some syndromes and complications (pain syndrome, acute circulatory insufficiency, abdominal syndromes, resorption-necrotic syndrome, etc.), improvement of the re-adaptation potential, and early recovery of myocardial metabolism, as evidenced by serial measurements of enzymemia and myoglobinemia, ECG monitoring from 12 leads, and cardiotopography from 35 leads, limiting the necrosis area and the ultimate size of myocardial damage. KPI treatment in the given doses produced no side effects.

Topics: Aprotinin; Drug Therapy, Combination; Electrocardiography; Humans; Infusions, Intravenous; Monitoring, Physiologic; Myocardial Infarction; Time Factors; Trypsin Inhibitors

The paper reports on the efficacy of the protease inhibitors Contrycal and Hordox in acute myocardial infarction. The authors observed 154 patients, of whom 50 constituted the control group. They used to watch the process in the myocardium with biochemical, radioimmune and electrocardiographic methods. It was established that Contrycal (Hordox) used in the combined therapy of acute myocardial infarction during the first hours of the disease is effective.

Topics: Adult; Aged; Aprotinin; Drug Evaluation; Electrocardiography; Humans; Kallikreins; Middle Aged; Myocardial Infarction; Protease Inhibitors; Time Factors; Trypsin Inhibitors